F2G

Bright Angel Therapeutics

This biotechnology company develops small molecule inhibitors to treat patients with drug-resistant and life-threatening fungal infections.

Elion Therapeutics

This biotechnology company develops antifungal medicines to prevent and treat life-threatening infections in immunocompromised patients, such as organ transplant and oncology recipients.

Pulmocide

This biopharmaceutical company develops inhaled antifungal medicines for patients with serious respiratory tract infections such as pulmonary aspergillosis.

Viamet Pharmaceuticals

This company develops small molecule antifungal medicines for patients with chronic and life-threatening infections using a proprietary metalloenzyme inhibitor design platform.

AdjutTec

This pharmaceutical company develops antibiotic resistance breakers to treat patients with multidrug-resistant bacterial and fungal infections.

Amplyx

This company develops antifungal and antiviral therapies for patients with compromised immune systems, such as cancer and transplant recipients.

Melinta Therapeutics

This biopharmaceutical company develops and commercialises antibiotics and antifungals to treat drug-resistant infections in hospital and clinic settings.

C10 PHARMA

This biopharmaceutical company develops novel antibiotics to treat life-threatening bacterial infections and combat antimicrobial resistance for patients with unmet medical needs.